Norroy Bioscience Co. Ltd. has prepared drug conjugates comprising a radionuclide linked to a ligand targeting glutamate carboxypeptidase II (NAALADase; NAAG peptidase, FOLH1; PSMA) through a linker for use as positron-emission tomography (PET) imaging agents.

Novartis AG has reported new cyclin-dependent kinase 2 (CDK2) inhibitors potentially useful for the treatment of cancer.

Work at Dice Alpha Inc. has led to the discovery of new interleukin-17A (IL-17A) production inhibitors. They are reported to be potentially useful for the treatment of psoriasis, radiographic axial spondyloarthritis (ankylosing spondylitis), hidradenitis suppurativa, spondyloarthritis, psoriatic and rheumatoid arthritis.

Regeneron Pharmaceuticals Inc. has patented new 17-β-hydroxysteroid dehydrogenase 13 (HSD17B13; 17-β-HSD-13) inhibitors reported to be useful for the treatment of liver diseases.

Recent Ideaya Biosciences Inc. patents describe new poly(ADP-ribose) glycohydrolase (PARG) inhibitors reported to be useful for the treatment of cancer.

Gasherbrum Bio Inc. has described glucagon-like peptide 1 receptor (GLP-1R) agonists reported to be useful for the treatment of type 2 diabetes.

Gilead Sciences Inc. has divulged nucleoside phospholipid compounds reported to be useful for the treatment of viral infections.

Chengdu Zeling Biomedical Technology Co. Ltd. has identified compounds acting as NLRP3 inflammasome inhibitors reported to be useful for the treatment of cancer, and inflammatory, autoimmune, cardiovascular, renal, gastrointestinal, respiratory and neurological disorders.

Chengdu Kanghong Pharmaceutical Co. Ltd. has synthesized indazolinone compounds acting as glucagon-like peptide 1 receptor (GLP-1R) agonists reported to be useful for the treatment of cardiovascular disorders, cerebral infarction, dementia, diabetes, hyperlipidemia, metabolic dysfunction-associated steatohepatitis (MASH; formerly nonalcoholic steatohepatitis [NASH]), obesity and stroke.

Apogee Pharmaceuticals Inc. has disclosed monoglyceride lipase (MGLL; MAGL) inhibitors reported to be useful for the treatment of neurodegeneration, neuropathy, ischemia, and metabolic, eye, lung, inflammatory and renal disorders, among others.